A novel rapamycin analog is highly selective for mTORC1 in vivo
oleh: Katherine H. Schreiber, Sebastian I. Arriola Apelo, Deyang Yu, Jacqueline A. Brinkman, Michael C. Velarde, Faizan A. Syed, Chen-Yu Liao, Emma L. Baar, Kathryn A. Carbajal, Dawn S. Sherman, Denise Ortiz, Regina Brunauer, Shany E. Yang, Stelios T. Tzannis, Brian K. Kennedy, Dudley W. Lamming
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2019-07-01 |
Deskripsi
Rapamycin extends lifespan in model organisms by targeting mTORC1, but exerts off-target side effects via inhibition of mTORC2. Here, the authors report the identification of a selective mTORC1 inhibitor, and show that it inhibits mTORC1 activity both in vitro and in vivo, with reduced side effects on glucose homeostasis, lipid metabolism, and the immune system.